INtRODUctION
Developmental status of a child is usually assessed in relation to events that take place during the progress of growth. Thus, chronological age, dental development, height and weight measurements, sexual maturation characteristics and skeletal age are some of the biological indicators that have been used to identify stages of growth. The use of dental age as an indicator for maturity is simple but not so accurate because of wide variations in time of eruption of teeth due to the influence of local and environmental factors. Accurate determination of skeletal maturity and remaining growth is crucial for many orthodontic, orthopaedic, orthognathic and dental implant timing decisions. Chronological age and dental age do not exactly corelate with sexual maturity. Cervical vertebrae stages and hand-wrist radiographs are currently used to identify peak mandibular bone growth. 1 Using hand-wrist radiographs to assess skeletal maturity was first described by Todd in his 1937 publication. The routine use of hand-wrist radiographs has recently been questioned due to ethical issues. Additional radiation expo sure is the primary concern. Hand-wrist radiographs have been shown to be poor predictors of the end of mandibular growth. Residual facial growth is of particular importance to relapse from orthopedic and orthognathic surgical corrections, as well as osseointegrated dental implant place ment. 2 Since lateral cephalometric radiographs are routinely taken for orthodontic patients, using the cervical vertebrae from these radiographs to assess skeletal maturity has been especially appealing to orthodontists. These are highly sub jec tive techniques that not only involve radiographic expo sure but also lack the ability to determine the intensity of the growth spurt and the end of growth. 1 In 1957, insulinlike growth factor I (IGFI) was dis covered by Salmon and Daughaday. Insulin-like growth factor I is a circu lating growth hormone-dependent factor whose level correlates with sexual maturity.
Insulinlike growth factor I is measurable in serum (in which it was first detected) as well as in urine and saliva. Salivary IGFI levels reflect its levels in the plasma. How ever, salivary IGFI levels are extremely low: less than 1% of serum levels. This makes accurate measurements difficult.
1
IGFI mediates most of the physiological actions of Growth Hormone on bone growth. It is reported that IGFI rapidly activates bone turnover, as it is the major factor that affects linear bone growth. There is significant corelation between sex hormones and IGFI. The estradiol levels of girls and testosterone levels of boys differed significantly between pubertal stages and increased with the proceeding stages. In both the sexes, serum IGFI levels were significantly correlated with sex steroid levels. 3 It was reported that mean serum IGFI (somatomedins) concentrations increased slowly in prepubertal children, with a further steep increase during puberty; after puberty, a subsequent continuous fall in circulating IGFI levels were apparent through adulthood. 4 It is reported that IGFI rapidly activates bone turnover and insulinlike growth factorbinding protein 3 (IGFBP3), the major binding protein of IGFI that has a direct role in the endocrine regulation of bone metabolism. In puberty, both total IGFI and IGFBP3 serum levels increase. Furthermore, the molar ratio between IGFI and IGFBP3 increases in puberty, suggesting that free IGFI increases in puberty when growth velocity is high.
5
Insulinlike growth factor I (IGFI) is a mediator for growth hormone (GH) that plays an essential role in both local and systemic regulation of bone growth. Recent studies have shown that the condylar cartilage is highly sensitive to the changes in IGFI concentrations. Several growth studies demonstrated that serum IGFI levels reflect serum GH levels but without the fluctuation involved with the latter. Therefore, IGFI levels have been used by endocrinologists to diagnose GH disturbances. Serum IGFI levels have also been related to chronologic age and sexual maturity stages, and have been shown to peak late in puberty. This peak is mainly due to the stimulation of GH secretion by adrenal and gonadal steroids. 6 Blood spot IGFI measurement is a relatively new, mini mally invasive technique and has an excellent corre lation with regular serum IGFI. In addition, the samples are stable at room temperature for upto 2 weeks. IGFI levels can also be measured from salivary samples. The disadvantage was that there was variation of the values throughout the day.
7
In this study, an attempt was made to correlate mean IGFI levels and cervical vertebrae stages, to assess the IGFI levels in the prepubertal, pubertal and postpubertal orthodontic patients, to correlate IGFI levels to skeletal maturity by using the cervical vertebral stages and to compare the mean IGFI levels at each of the stages, to identify if there is any gender variation in the IGFI values among the different CS. Also, a hypothesis was made that IGFI levels would also correlate with cervical stages that corresponds to the greatest amount of facial growth.
MAtERIALS AND MEtHODS
Blood spot samples of 90 individuals were collected of both the sexes between age group of 10 and 25 years, and their corresponding lateral cephalograms were obtained. The samples were divided into four groups based on the age, which were between 1013 years, 1417 years, 1821 years and 2225 years. Cervical vertebrae was divided into six stages: CS 1 to CS 6, which were initiation, acceleration, transition, deceleration, maturation and completion stages. Out of the 90 individuals, 49 (55%) were females and 41 (45%) were males.
Patients included in the study were the ones to begin ortho dontic treatment, patients undergoing orthodontic treatment, and post-treatment follow-up cases. Exclusion criteria included patients with systemic illness (liver and kidney disease), growth abnormality and bleeding disorders. As IGFI is synthesized in the liver and metabolized in the kidney, patients with liver and kidney disorders were not included in the study.
Informed consent was taken from the patient. Parent's or guardian's blood sample was collected using sterile lancet, under aseptic precaution using 'S and S 903 filter paper'. Samples were stored at -20° in a deep freezer. Samples were sent for laboratory evaluation of IGFI level by radioimmunoassay. Active IGFI ELISA kit was used for immunoassay.
The CS (cervical stage) technique as described by Baccetti et al was used to stage the cervical vertebrae. In this technique, the second, third and fourth cervical vertebrae were examined. Curvatures were defined when the depth of curvature was greater than 1 mm. Linear correlations were performed to deter mine the IGFI trends relating to the various cervical skeletal maturation stages. 8 IGFI enzymelinked immunosorbent assay (ELISA) was used for the quantitative measurement of IGFI in serum or plasma. It is an enzymatically amplified 'onestep' sandwich type immunoassay. The assay included an extraction step in which IGFI was separated from its binding protein in serum.
Extraction Procedure
The samples were labelled with Laboratory IDs and a tem plate was made. The dried blood spots (DBSs) are punched into the round-bottomed microplate. To the dried blood spots, 225 ml of extraction solution was added and, after shaking it well, was incubated for 60 minutes at room temperature.
During the extraction period, fifty microliters of neu tra lizing solution was added to all tubes labeled for neu tra lization. After neutralization, 100 ml of sample dilutents was added to another dilution microplate. Fifty microliters of neutralized extract was added to the corres ponding dilution microplate and shook well.
Assay Procedure
The microtitration strips to be used were marked. Twenty microliters of each standard, control and diluted unknown extract were pipetted to the appropriate wells.
The antibody enzyme conjugate solution was prepared by diluting the IGFI antibody enzyme conjugate concentrate with the assay buffer. One hundred microliters of antibody enzyme conjugate solution were added to each well using a dispenser. The wells were incubated shaking at a fast speed (500700 rpm) on an orbital microplate shaker, for 2 hours at room temperature. It was aspirated and each well was washed with the wash lotion using an automatic microplate washer. It was then blot dried by inverting the plate on absorbent microplate washer. One hundred microliters of the TMB chromogen solution were added to each well using a semiautomatic dispenser. The wells were incubated, shaking at a fast speed (500700 rpm) on an orbital microplate shaker, for 10 minutes at room temperature. One hundred microliters of the stopping solution to each well were added using a semi-automatic dispenser.
The absorbance of the solution in the wells within 30 minutes was read, using microplate reader set at 450 nm. 9 Analysis of variance (ANOVA) and posthoc test was used to compare mean IGFI levels and corresponding cervical maturation stages. The proportion was compared using Chisquare test of significance. In all the above tests, pvalue less than 0.05 was taken to be statistically significant. The data were analyzed using statistical package for social science (SPSS, V 10.5).
RESULtS
The results showed that the IGFI levels were low at pre pubertal levels (CS 1, CS 2, CS 3), it increased gradually, peaking during puberty showing maximum values (CS 4, CS 5), which later dropped to reach prepubertal values (CS 6). The mean values of IGFI (ng/ml), in CS 1 stage, Table 1) .
Comparison of mean IGFI (ng/mg) according to CS stage by gender were as follows: in males, it was 100.94 ng/ml in CS 1 stage, 130.36 ng/ml in CS 2, 148.69 ng/ml in CS 3, 218.04 ng/ml in CS 4 stage, 301.38 ng/ml in CS 5 and 120.61 ng/ml in CS 6 stage, while in females, the mean IGFI levels were 117.01 ng/ml in CS 1, 144.87 ng/ml in CS 2, 144.78 ng/ml in CS 3, 222.32 ng/ml in CS 4, 248.88 ng/ml in CS 5 and 118.62 ng/ml in CS 6 ( Table 2) .
DIScUSSION
IGFI levels are low at the prepubertal stages of cervical development. There was an increase in IGFI levels from CS3 to CS4, and maximum at CS5 stage. There was a decline between CS5 and CS6 stages. Mean IGFI levels at CS4 and CS5 were significantly higher than at the other stages. These findings can be compared with the study done by Mohamed Masoud in which the mean IGFI level in CS 1 was 182.0074 microgram/L. In CS 2, it was 212.1 microgram/L. In CS 3, it was 208.68 micrograms/L and in CS 4, the mean IGFI levels were 335.89 micrograms/L, in CS 5, it was 406.82 micrograms/L and 199.75 micrograms/L in CS 6.
1
In addition to radiation exposure and the subjectivity of staging the X-rays, an inherent disadvantage of handwrist radiographs and cervical vertebra staging is that the final stage of development does not necessarily indicate the completion of growth, especially mandibular growth. Several studies have shown that mandibular growth continues after radiographic skeletal maturity. 10 Our results showed that IGFI levels were still relatively high in many subjects, who were at CS 6 and had supposedly completed their growth. In that stage, we found that IGFI levels were negatively correlated with time since the onset of puberty. Thus, IGFI might be a good indicator of residual mandibular growth. Further studies of longitudinal data are underway to evaluate this.
Optimal treatment timing in orthodontics and dentofacial orthopedics can be assessed and determined by skeletal maturation. It has been advocated that orthopedic treatment of Class III malocclusion for maxillary protraction is more effectively performed at the prepubertal stage than at puberty. Thus, if maxillary protraction is indicated, treatment should be performed before CS stages I and II. At these stages, the IGFI level is lower.
Pubertal growth begins at CS III which correlates with the beginning of increase in IGFI levels. Between CS III and CS IV, there is a rapid increase in IGFI levels. Peak mandibualar growth occurs between CS III and CS V when the IGFI levels are the maximum.
IGFBP3 is a carrier for IGFI, meaning that IGFI binds IGFBP3, creating a complex whose combined molecular weight and binding affinity allow the growth factor to have an increased half-life in serum. Without binding to IGFBP3, IGFI is cleared rapidly through the kidney, due to its low molecular weight. But when bound to IGFBP3, IGFI evades renal clearance. Also, since IGFBP3 has a lower affinity for IGFI than IGFI has for its receptor, IGFR, its binding does not interfere with IGFI function. For these reasons, an IGFI/IGFBP3 combination approach was approved for human treatment. IGFI has also been shown to be effective in animal models of stroke when combined with Erythropoietin. Both behavioral and cellular improvements were found.
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IGFI administration is used for the treatment of retarded growth or growth failure. 12 IGFI hormonal therapy has a pathogenic role in cancer. Studies have shown that increased levels of IGF lead to increased growth of existing cancer cells.
13
Studies have shown chronic IGFI administration leads to mitochondrial dysfunction and reduced cell viability. 14 Insulin-like growth factor I is a mediator for growth hormone (GH) that plays an essential role in both local and systemic regulation of bone growth. IGFI levels have been shown to depend on GH before puberty. However, during puberty, IGFI levels can also be independent of GH because IGFI production can be directly stimulated by androgens.
15,16
Recent studies have also shown that the condylar cartilage is highly sensitive to changes in IGFI concentrations. Several growth studies demonstrated that serum IGFI levels reflect serum GH levels but without the fluctuation involved with the latter. Therefore, IGFI levels have been used by endocrinologists to diagnose GH disturbances. Serum IGFI levels have also been related to chronologic age and sexual maturity stages, and have been shown to peak late in puberty. This peak is mainly due to the stimulation of GH secretion by adrenal and gonadal steroids.
17,18
The advantages of using IGFI immunoassay method for assessment of skeletal maturity over other radiographic techniques was accuracy. Inter-examiner and intra-examiner variations are ruled out, which is seen with the radiographic techniques. Additional radiographic exposure to the patient is avoided. Residual mandibular growth can be accurately assessed using this technique.
The disadvantages include difficulties in storage and transport of the samples to the laboratory for analysis. The patient cooperation for collection of sample among the younger children is difficult. Also this technique is not very cost effective.
cONcLUSION
• Blood spot IGFI correlates well with skeletal age as determined by radiographic techniques.
• Blood spot IGFI levels are low in the prepubertal cervical stages.
• They rise sharply to their peak during pubertal CS stages, and then decline to prepubertal levels.
• IGFI can act as a potential skeletal maturity indicator, without the hazard of additional radiographic exposure.
• Longitudinal data are needed to confirm the usefulness of this technique to accurately determine the timing of a patient's growth spurt and to determine whether IGFI levels are good predictors of residual mandibular growth.
• In most of the CS stages, the mean IGFI values were higher in females compared to males, but not significantly higher.
